The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results.

References and Resources
Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008 July(5):213-17.

Sponsored by The Do